Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here the bang will be great!
Long wait big bang
now let's start thinking!
MC still low!
tomorrow could be interesting!
Who are you referring to with VR?
Ok today we will see an updated business plan!
Come on Richie show us how a good boy you are!
make us dream!
I was referring to those who answered not to you!
in the meantime I add
A 3.900 1,89 IMM 0,00 09/06
A 4.300 1,91 ESEG 1,91 09/06
A 2.650 1,90 ESEG 1,90 09/06
I have to disconnect!
See you later
Ah $ 1.91 +4300 for me!
There are others below but I have a feeling they won't close!
Since shorts are always one step ahead and they know a lot!
I ask THEM:
Do you think a US company owned by a Canadian company can ask for the Innovation and Competition Act's funds?
I'm waiting for the bell to ring!
Thanks for now!
I know what I will buy!!!
Ther’s Titan Medical USA Inc.
Today I cannot participate in the AGM but if I participated I would ask if they intend to access the funds.
A statement from them would be very interesting!
250 bil is a lot!
100 mil are enough for us!
For me McNally is OK!
Thanks McNally
OTB
someone covers ... I don't sell!
So undervalue
How did the inspection go?
But if everything goes well will they tell us or will the approval be communicated directly?
ARE YOU READY?
Last tickets before it leaves unexpectedly!
bluebird bio to Present at Goldman Sachs Global Healthcare Conference
Today
The arrangement described by Malkowski et al. could be complicated to assemble due to the springs in the links and is likely to require careful manipulation by an operator who must be mindful to counteract the bias exerted by the springs to avoid undesired straightening of the articulable segments.
SUMMARY
The present invention provides an alternative articulated tool positioning apparatus that avoids the need for springs biasing articulated segments into a straight position through the use of cables capable of tension and compression connecting terminating members between articulating links, thereby supporting both pushing and pulling on the cables and providing for simpler assembly.
In accordance with one aspect of the invention, there is provided an articulated tool positioning apparatus. The apparatus includes a base member, an intermediate member, an end member and a first tool holder arranged in succession, each of the base member, intermediate member, end member and tool holder having a respective central opening.
https://pdfpiw.uspto.gov/.piw?PageNum=0&docid=10945748&IDKey=0D1B09CB0C1B%0D%0A&HomeUrl=http%3A%2F%2Fpatft.uspto.gov%2Fnetacgi%2Fnph-Parser%3FSect1%3DPTO2%2526Sect2%3DHITOFF%2526p%3D1%2526u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-bool.html%2526r%3D1%2526f%3DG%2526l%3D50%2526co1%3DAND%2526d%3DPTXT%2526s1%3D%252522titan%252Bmedical%252522%2526OS%3D%252522titan%252Bmedical%252522%2526RS%3D%252522titan%252Bmedical%252522
https://pdfpiw.uspto.gov/.piw?PageNum=3&docid=10945748&IDKey=0D1B09CB0C1B%0D%0A&HomeUrl=http%3A%2F%2Fpatft.uspto.gov%2Fnetacgi%2Fnph-Parser%3FSect1%3DPTO2%2526Sect2%3DHITOFF%2526p%3D1%2526u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-bool.html%2526r%3D1%2526f%3DG%2526l%3D50%2526co1%3DAND%2526d%3DPTXT%2526s1%3D%252522titan%252Bmedical%252522%2526OS%3D%252522titan%252Bmedical%252522%2526RS%3D%252522titan%252Bmedical%252522
https://pdfpiw.uspto.gov/.piw?PageNum=6&docid=10945748&IDKey=0D1B09CB0C1B%0D%0A&HomeUrl=http%3A%2F%2Fpatft.uspto.gov%2Fnetacgi%2Fnph-Parser%3FSect1%3DPTO2%2526Sect2%3DHITOFF%2526p%3D1%2526u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-bool.html%2526r%3D1%2526f%3DG%2526l%3D50%2526co1%3DAND%2526d%3DPTXT%2526s1%3D%252522titan%252Bmedical%252522%2526OS%3D%252522titan%252Bmedical%252522%2526RS%3D%252522titan%252Bmedical%252522
they made a bet!
Perhaps MDT offered the most tempting project!
They must not have found the right place or there was a need to develop something!
MDT will acquire TMDI when it has laid the egg!
Not simple but affordable!
GO TMDI GO!
Thanks a little to TRXC too!
Today I wanted to buy more TMDI but had to add elsewhere! I hope fate will assist me and I will buy many more shares here!
Today many unexpected gains and one very unexpected loss (just + 2% but it s like a loss)!
Crazy day
OTB
In a short time it is the second Buy on the news that happens to me!
Did they change the strategy?
Who first understands first earns!
The whole wallet is largely green!
Only NVIV (understandable) and BLUE (incomprehensible) are red!
I never thought I'd rack up today after the news!
In BLUE my average price is $ 28 after today!
You have to sell a lot more to scare me!
Whoever sells this now is just a damn jerk!
I SCOOOP EM
Remember that the FDA loves those who submit as BLUE!
Very diligent
WE WANT TO SEE A BEAUTIFUL SHORT SQUIZEEEEEE BIDDA in yourASS
BUAHAHAHAHAHAAHHAAHAHHAAHAHAHAHHAHA
SCOOOPEM
ALL YOU CAN BUY!
I got to 1000!
But who's the jerk selling?
CRSP $86 B
BLUE $2 B (1 B cash)
Who is undervalue?
Come on, only you are missing!
I would like to add a little something!
Yselty® for uterine fibroids:
– Submitting an NDA (New Drug Application) to the US Food & Drug Administration (Q2)
– Securing European marketing approval (Q4)
– Preparing for commercial launch
• Yselty® for endometriosis:
– Yielding topline data from the EDELWEISS 3 Phase 3 study (Q4)
• Ebopiprant:
– Initiating a Phase 2b dose ranging study (EU and Asia) (Q4)
– Discussing US clinical development with the FDA
• New opportunities:
– Exploring new indications, including the potential development of linzagolix in prostate
cancer treatment
– Seeking suitable strategic partnerships or other commercialization arrangements that
properly balance the current development needs with our retention of product value
On June 7, 2021, bluebird bio, Inc. (the "Company" or "bluebird") issued a press release to announce that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin for sickle cell disease (SCD) gene therapy (bb1111) for adult and pediatric patients with SCD, and the Phase 3 Northstar-2 (HGB-207) and Northstar-3 (HGB-212) studies of betibeglogene autotemcel gene therapy (beti-cel; licensed as ZYNTEGLO™ in the European Union and the United Kingdom) for adult, adolescent and pediatric patients with transfusion-dependent ß-thalassemia (TDT). The Company is working closely with study investigators and clinical trial sites to resume all study activities as soon as possible.
here we go!
anyhow
I am not selling my shares under $ 50!
Fill the gap!
BIG
How long should we wait to see 5% or + in MDT's hand?
We need an antivirus that is durable and easy to keep!
An effective cure is fine too!
It would also be necessary to be able to monitor the level of individual protection, for the groups that are at risk!
CAME ON TNXP!
Wow how much attention!
In my opinion the bull horns the red!
But the swing here is crazy!
Suggestions on the next?
If you tell me yours I tell you what it will be in my opinion!
Welcome in pvt
Unreal!
congratulations to those who believed in it and held out for so long!
Nice to see the shorts burning each other!
Now the question is: Who will be next?